88 related articles for article (PubMed ID: 29256535)
1. Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
Hussain M; Shad MN; Akhtar L
J Pak Med Assoc; 2017 Dec; 67(12):1884-1888. PubMed ID: 29256535
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients.
Hussain M; Atif MA; Ghafoor MB
Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2385-2389. PubMed ID: 28167482
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone improves serum lipid profile in diet induced hyperlipidaemic non diabetic rats.
Hussian M; Arain AQ; Chiragh S
J Pak Med Assoc; 2016 Oct; 66(10):1286-1290. PubMed ID: 27686305
[TBL] [Abstract][Full Text] [Related]
4. Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Ashraf R; Amir K; Shaikh AR
J Pak Med Assoc; 2005 Aug; 55(8):324-7. PubMed ID: 16164158
[TBL] [Abstract][Full Text] [Related]
5. [The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia].
Jian J; Hao X; Deng C; Zhou H; Lin J
Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):517-9. PubMed ID: 11798687
[TBL] [Abstract][Full Text] [Related]
6. Effect of gemfibrozil on the pharmacokinetics of pioglitazone.
Deng LJ; Wang F; Li HD
Eur J Clin Pharmacol; 2005 Dec; 61(11):831-6. PubMed ID: 16283275
[TBL] [Abstract][Full Text] [Related]
7. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.
Spencer CM; Barradell LB
Drugs; 1996 Jun; 51(6):982-1018. PubMed ID: 8736620
[TBL] [Abstract][Full Text] [Related]
8. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
9. Bladder Cancer In Patients With Type 2 Diabetes Treated With Pioglitazone, A Comparative Study.
Riaz A; Khan K; Afreen B; Kazmi I
J Ayub Med Coll Abbottabad; 2018; 30(3):356-359. PubMed ID: 30465366
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
11. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
[TBL] [Abstract][Full Text] [Related]
13. Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients.
Ok E; Kursat S; Alev M; Tobu M; Tokat Y; Akcicek F; Hoscoskun C; Basci A
Nephron; 1996; 73(3):491-2. PubMed ID: 8832618
[No Abstract] [Full Text] [Related]
14. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Jen SL; Chen JW; Lee WL; Wang SP
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
[TBL] [Abstract][Full Text] [Related]
16. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
Silverberg MJ; Leyden W; Hurley L; Go AS; Quesenberry CP; Klein D; Horberg MA
Ann Intern Med; 2009 Mar; 150(5):301-13. PubMed ID: 19258558
[TBL] [Abstract][Full Text] [Related]
17. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
18. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
[TBL] [Abstract][Full Text] [Related]
19. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study.
Zema MJ
J Am Coll Cardiol; 2000 Mar; 35(3):640-6. PubMed ID: 10716466
[TBL] [Abstract][Full Text] [Related]
20. Association of Serum Triglyceride Level and Gemfibrozil Consumption With Periodontal Status.
Sayar F; Akhondi N; Fallah S; Moalemnia AA; Cheraghi A
J Periodontol; 2017 May; 88(5):457-463. PubMed ID: 27958766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
